Taha, Absar J.
HRN: 22-23-49 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/22/2022
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
11/22/2022
11/28/2022
ORAL
1.2ml
Q12Hrs
PCAP-C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes